Hanmi Science Co Ltd
KRX:008930

Watchlist Manager
Hanmi Science Co Ltd Logo
Hanmi Science Co Ltd
KRX:008930
Watchlist
Price: 44 550 KRW 1.48% Market Closed
Market Cap: 3T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Hanmi Science Co Ltd stock under the Base Case scenario is 24 894.67 KRW. Compared to the current market price of 44 550 KRW, Hanmi Science Co Ltd is Overvalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
24 894.67 KRW
Overvaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
46
vs Industry
60
Median 3Y
2
Median 5Y
2.2
Industry
2.6
More Details
57.2
P/E
P/E
Price to Earnings
57.2
vs History
38
vs Industry
13
Median 3Y
31.3
Median 5Y
42.3
Industry
21.5
More Details
37
P/OCF
P/OCF
Price to OCF
37
vs History
85
vs Industry
18
Median 3Y
87.9
Median 5Y
140
Industry
16.6
More Details
49.4
P/FCFE
P/FCFE
Price to FCFE
49.4
vs History
80
vs Industry
16
Median 3Y
166.4
Median 5Y
198.9
Industry
24
More Details
3.6
P/B
P/B
Price to Book Value
3.6
vs History
44
vs Industry
33
Median 3Y
2.9
Median 5Y
3.4
Industry
2.1
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
46
vs Industry
58
Median 3Y
2.1
Median 5Y
2.4
Industry
2.7
More Details
12.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.7
vs History
60
vs Industry
25
Median 3Y
11.8
Median 5Y
15.6
Industry
5.3
More Details
94.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
94.5
vs History
31
vs Industry
8
Median 3Y
51.5
Median 5Y
80
Industry
12.8
More Details
133.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
133.1
vs History
23
vs Industry
7
Median 3Y
61.9
Median 5Y
103.6
Industry
16.2
More Details
38.5
EV/OCF
EV/OCF
Enterprise Value to OCF
38.5
vs History
85
vs Industry
17
Median 3Y
95.4
Median 5Y
143
Industry
14.9
More Details
46.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
46.2
vs History
85
vs Industry
17
Median 3Y
140.1
Median 5Y
229.6
Industry
17.7
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
44
vs Industry
38
Median 3Y
2.3
Median 5Y
2.6
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hanmi Science Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hanmi Science Co Ltd
KRX:008930
3.1T KRW 2.3 57.2 94.5 133.1
US
Eli Lilly and Co
NYSE:LLY
744B USD 15.2 67 36 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
362.6B USD 4.1 16.6 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.1 20.5 14.1 16.2
CH
Roche Holding AG
SIX:ROG
206.1B CHF 3.4 24.9 9.4 10.9
CH
Novartis AG
SIX:NOVN
186.1B CHF 4.3 17.7 10.4 14
UK
AstraZeneca PLC
LSE:AZN
163.6B GBP 4 28.3 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
199.5B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
135.8B USD 2.2 17.2 7.4 10.4
P/E Multiple
Earnings Growth PEG
KR
Hanmi Science Co Ltd
KRX:008930
Average P/E: 29
57.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.6
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.2
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Hanmi Science Co Ltd
KRX:008930
Average EV/EBITDA: 402.8
94.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Hanmi Science Co Ltd
KRX:008930
Average EV/EBIT: 1 709.6
133.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
14%
1.2
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.